Related Experiment Video
Updated: Apr 4, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Stimuli-Responsive Nanoparticles for siRNA Delivery
Josimar O Eloy, Raquel Petrilli, Renata F V Lopez
1College of Pharmacy, The Ohio State University, Columbus, 500 W 12th Ave, Columbus, OH 43210, USA. lee.1339@osu.edu.
Abstract:
Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for "on demand" delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these "smart" nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
More Related Videos
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

